These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 33866336)
1. Role of Can C; Gündoğan C; Yildirim OA; Poyraz K; Güzel Y; Kömek H Hell J Nucl Med; 2021; 24(1):25-35. PubMed ID: 33866336 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients. Oruç Z; Güzel Y; Ebinç S; Kömek H; Küçüköner M; Kaplan MA; Oruç İ; Urakçi Z; Işikdoğan A Nucl Med Commun; 2021 Dec; 42(12):1336-1346. PubMed ID: 34366407 [TBL] [Abstract][Full Text] [Related]
3. Correlations between whole body volumetric parameters of Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097 [TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Clinical Factors That Influence Repeat Thin P; Hotta M; Gafita A; Grogan T; Czernin J; Calais J; Sonni I J Nucl Med; 2024 Oct; 65(10):1571-1576. PubMed ID: 39168522 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital. Sangiwa BA; Burger C; Ellmann A Pan Afr Med J; 2024; 48():30. PubMed ID: 39220559 [TBL] [Abstract][Full Text] [Related]
7. The superior detection rate of total-body [ Wang Y; Dong L; Zhao H; Li L; Huang G; Xue W; Liu J; Chen R Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2484-2494. PubMed ID: 38514483 [TBL] [Abstract][Full Text] [Related]
8. A pictorial view on false positive findings of Dancheva Z; Chausheva S; Stoeva T; Dyankova M; Yordanova T; Chaushev B; Marinov R; Nikolov V; Abushev P; Todorov G; Dimitrova E; Klisarova A; Anakievski D Hell J Nucl Med; 2024; 27(1):16-26. PubMed ID: 38629815 [TBL] [Abstract][Full Text] [Related]
9. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731 [TBL] [Abstract][Full Text] [Related]
10. Direct Patlak Reconstruction of [ Rasul S; Geist BK; Einspieler H; Fajkovic H; Shariat SF; Schmitl S; Mitterhauser M; Bartosch R; Langsteger W; Baltzer PAT; Beyer T; Ferrara D; Haug AR; Hacker M; Rausch I Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37761975 [TBL] [Abstract][Full Text] [Related]
11. Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716 [TBL] [Abstract][Full Text] [Related]
12. Recurrent prostate cancer: combined role for MRI and PSMA-PET in Jannusch K; Bruckmann NM; Morawitz J; Boschheidgen M; Quick HH; Herrmann K; Fendler WP; Umutlu L; Stuschke M; Hadaschik B; Antoch G; Schimmöller L; Kirchner J Eur Radiol; 2024 Jul; 34(7):4789-4800. PubMed ID: 38038758 [TBL] [Abstract][Full Text] [Related]
13. Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience. Okudan B; Coşkun N; Seven B; Atalay MA; Yildirim A; Görtan FA Nucl Med Commun; 2021 Nov; 42(11):1254-1260. PubMed ID: 34284438 [TBL] [Abstract][Full Text] [Related]
14. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, Akkaya H; Dilek O; Özdemir S; Taş ZA; Öztürk İS; Gülek B Diagn Interv Radiol; 2023 Sep; 29(5):647-655. PubMed ID: 37395389 [TBL] [Abstract][Full Text] [Related]
15. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy. Michalski K; Mix M; Meyer PT; Ruf J Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145 [TBL] [Abstract][Full Text] [Related]
17. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589 [TBL] [Abstract][Full Text] [Related]
18. Comparison of discovery rates and prognostic utility of [ Kluge K; Einspieler H; Haberl D; Spielvogel C; Amereller D; Egger G; Kramer G; Grubmüller B; Shariat S; Hacker M; Kenner L; Haug A Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2833-2842. PubMed ID: 38693454 [TBL] [Abstract][Full Text] [Related]
19. Impact of 68Ga-PSMA PET/CT on Survival and Management in Prostate Cancer. Algın E; Okudan B; Açıkgöz Y; Sayan H; Bal Ö; Seven B Curr Med Imaging; 2024; 20():e15734056276494. PubMed ID: 38284703 [TBL] [Abstract][Full Text] [Related]
20. Intraindividual comparison between Spohn S; Jaegle C; Fassbender TF; Sprave T; Gkika E; Nicolay NH; Bock M; Ruf J; Benndorf M; Gratzke C; Grosu AL; Zamboglou C Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2796-2803. PubMed ID: 32342192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]